Conference Report

New Data on Viral Hepatitis and Related Complications

Source: CCO Independent Conference Coverage of the Digestive Disease Week 2006*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

New Data on Viral Hepatitis and Related Complications

Faculty:

Nezam H. Afdhal, MD, FRCPI
Kris V. Kowdley, MD, FACP

CREDIT INFORMATION

Release Date: July 21, 2006

Expiration Date: July 20, 2007

Physicians: maximum of 1.0 AMA PRA Category 1 Credit™

Status: The activity is not currently available for credit.

Learning Objectives

Upon completion of this activity, participants should be able to:

Discuss recent clinical data on the treatment of chronic hepatitis C with investigational or approved agents, including treatment in patients with comorbidities
Recount new findings on the treatment of chronic hepatitis B with approved or investigational agents
Describe progress in the development of noninvasive markers for the treatment of NAFLD and NASH

Topics covered include:

Overview
Data from the WIN-R Trial
Peginterferon Alfa-2a Retreatment in Previous Nonresponders
High-Dose Albumin Interferon in Prior Nonresponders
VX-950 Plus Peginterferon/Ribavirin in Treatment-naive Genotype 1 Patients
Dose-Ranging Study of the Polymerase Inhibitor HCV-796
Response to HCV Therapy in Hispanic Patients
Peginterferon Plus Ribavirin in Adolescents with Genotype 4 HCV
Treating Hepatitis C in Patients with Thalassemia and Sickle Cell Disease
Eltrombopag for HCV-Associated Thrombocytopenia
Entecavir in HBeAg-Negative Patients
Histologic Improvement with Entecavir
Telbivudine vs Adefovir in HBeAg-Positive Patients
HBV Viral Breakthrough and ALT Flares
Treating Multidrug-Resistant HBV
Noninvasive Markers for NAFLD and NASH

Disclaimer: The materials published on the Clinical Care Options Sites reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.